Incyte's Pipeline Potential Signals Massive Upside For Investors [Seeking Alpha]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Seeking Alpha
INCY's non-Jakafi portfolio is rapidly expanding, with Opzelura and oncology assets driving double-digit growth and significant margin improvement. Management targets 15–20% five-year sales CAGR and $3–4B ex-Jakafi revenue by 2030, diverging from consensus' negative growth view. Upcoming catalysts include the mid-2026 launch of Jakafi XR and potential approvals for Povorcitinib, providing a defensive bridge against the 2028 patent cliff. My valuation model implies 33% upside in 12 months, with execution on pipeline commercialization as the key risk. Looking for a helping hand in the market? Members of Beyond the Wall Investing get exclusive ideas and guidance to navigate any climate. Learn More » Liubomyr Vorona/iStock via Getty Images Buying Incyte on Strong Financials and Discounted Valuation Incyte Corporation INCY ) is a $19 billion market cap biotech company that offers a diverse pipeline of therapies for cancer, blood disorders, and dermatology. What's notable for
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte: Buy For The Turnaround, Stay For The Pipeline [Seeking Alpha]Seeking Alpha
- Factbox-Pharma sector doubles down on AI amid hopes of slashing costs, timelines [Yahoo! Finance]Yahoo! Finance
- Earnings Preview: What To Expect From Incyte's Report [Yahoo! Finance]Yahoo! Finance
- Why Incyte (INCY) Stock Is Trading Up Today [Yahoo! Finance]Yahoo! Finance
- Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity [CNBC]CNBC
INCY
Earnings
- 10/28/25 - Beat
INCY
Sec Filings
- 1/8/26 - Form 4
- 1/7/26 - Form 4
- 1/7/26 - Form 144
- INCY's page on the SEC website